Unknown PHASE4 INTERVENTIONAL 2-arm NCT01992198

Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis

Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis

Sponsor: Erzhen Chen

Conditions Pancreatitis,Acute Necrotizing

Interventions Meropenem Somatostatin cefoperazone + metronidazole enteral nutrition oral care by chlorhexidine gluconate

Updated 5 times since 2017 Last updated: Nov 18, 2013 Started: Jul 31, 2012 Primary completion: Dec 31, 2015 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Pancreatitis,Acute Necrotizing and is currently ongoing. Erzhen Chen leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Erzhen Chen
RenJi Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China